Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Triple Negative Breast Cancer (TNBC) is one of the most aggresive types of breast cancer. It’s the kind of breast cancer that doesn’t have estrogen receptors, progesterone receptors, and human ...

Friends, have you heard of triple-negative breast cancer [TNBC]? It’s a particularly aggressive type of breast cancer that can grow and spread faster than other types of breast cancer and has a higher ...

The ZEST trial, a phase 3 study on MRD-guided therapy in breast cancer, was terminated early due to low randomization rates. ctDNA was most frequently detected within six months post-treatment, ...

From left to right, Dr. Fernando Lecanda, Dr. Karmele Valencia, and Dr. Rafael Martínez Monge, from the Adhesion and Metastasis group at Cima, with Dr. Borja Ruiz-Fernández de Córdoba, also author of ...

Breast cancers can be classified into subgroups that hint at the aggressiveness of the cancer and the likelihood that the ...

The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients ...

SAN ANTONIO – Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better ...

MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (EXAS), a leading provider of cancer screening and diagnostic tests, today announced the first clinical study results from its Oncodetect ® ...